Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
OVID

OVID - Ovid therapeutics Inc Stock Price, Fair Value and News

0.78USD0.00 (0.00%)Market Closed

Market Summary

OVID
USD0.780.00
Market Closed
0.00%

OVID Stock Price

View Fullscreen

OVID RSI Chart

OVID Valuation

Market Cap

55.3M

Price/Earnings (Trailing)

-1.09

Price/Sales (Trailing)

186.74

EV/EBITDA

-0.49

Price/Free Cashflow

-1.1

OVID Price/Sales (Trailing)

OVID Profitability

EBT Margin

-17101.38%

Return on Equity

-64.74%

Return on Assets

-38.5%

Free Cashflow Yield

-91.14%

OVID Fundamentals

OVID Revenue

Revenue (TTM)

296.3K

Rev. Growth (Yr)

882.27%

Rev. Growth (Qtr)

45.4%

OVID Earnings

Earnings (TTM)

-50.7M

Earnings Growth (Yr)

12.44%

Earnings Growth (Qtr)

23.68%

Breaking Down OVID Revenue

Last 7 days

-76.3%

Last 30 days

-75.8%

Last 90 days

-75.6%

Trailing 12 Months

-79.1%

How does OVID drawdown profile look like?

OVID Financial Health

Current Ratio

10.47

OVID Investor Care

Shares Dilution (1Y)

0.60%

Diluted EPS (TTM)

-0.73

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
2023850.6K198.4K296.3K0
2022167.0M84.3M42.9M1.5M
202161.6M110.5M159.4M208.4M
202000012.6M

Tracking the Latest Insider Buys and Sells of Ovid therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 18, 2024
levin jeremy m
bought
50,364
2.76
18,248
ceo
Feb 22, 2024
rona jeffrey a
acquired
-
-
28,125
cbfo
Feb 22, 2024
perone thomas michael
acquired
-
-
28,125
general counsel, secretary
Feb 22, 2024
tardio jason
acquired
-
-
28,125
chief operating officer
Dec 04, 2023
levin jeremy m
gifted
-
-
-1,146,550
ceo
Sep 12, 2022
tardio jason
sold
-37,289
2.15
-17,344
chief operating officer
Jul 01, 2022
takeda pharmaceutical co ltd
sold
-
-
-5,750,000
-
Jul 01, 2022
takeda pharmaceutical co ltd
acquired
-
-
5,750,000
-
Jul 14, 2021
rakhit amit
sold
-126,203
3.71
-34,017
president and cmo
Jul 14, 2021
rakhit amit
acquired
64,292
1.89
34,017
president and cmo

1–10 of 16

Which funds bought or sold OVID recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.04
15,416
41,416
-%
May 20, 2024
Virtu Financial LLC
sold off
-100
-78,000
-
-%
May 17, 2024
Artal Group S.A.
unchanged
-
-425,000
7,625,000
0.19%
May 16, 2024
JANE STREET GROUP, LLC
added
5.26
-482
163,419
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.92
-13,319
18,285
-%
May 15, 2024
ADAR1 Capital Management, LLC
added
24.16
7,508
50,160
0.01%
May 15, 2024
PRELUDE CAPITAL MANAGEMENT, LLC
new
-
77,943
77,943
-%
May 15, 2024
Tower Research Capital LLC (TRC)
added
450
59,499
73,612
-%
May 15, 2024
EcoR1 Capital, LLC
unchanged
-
-1,039,960
18,658,100
0.47%
May 15, 2024
Squarepoint Ops LLC
added
500
171,799
208,446
-%

1–10 of 48

Are Funds Buying or Selling OVID?

Are funds buying OVID calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own OVID
No. of Funds

Unveiling Ovid therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
madison avenue partners, lp
5.2%
3,648,509
SC 13G/A
Feb 14, 2024
levin jeremy m
9.4%
6,942,181
SC 13G/A
Feb 12, 2024
rubric capital management lp
7.52%
5,315,969
SC 13G/A
Jan 29, 2024
blackrock inc.
6.1%
4,319,918
SC 13G
Jul 31, 2023
madison avenue partners, lp
5.1%
3,609,054
SC 13G
Feb 14, 2023
levin jeremy m
10.0%
7,281,121
SC 13G/A
Feb 14, 2023
biotechnology value fund l p
5.2%
3,631,500
SC 13G/A
Feb 13, 2023
stonepine capital management, llc
0%
0
SC 13G/A
Feb 10, 2023
ecor1 capital, llc
8.7%
6,117,400
SC 13G/A
Feb 10, 2023
rubric capital management lp
9.69%
6,828,065
SC 13G

Recent SEC filings of Ovid therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 17, 2024
8-K
Current Report
Jun 07, 2024
8-K
Current Report
May 14, 2024
S-8
Employee Benefits Plan
May 14, 2024
8-K
Current Report
May 14, 2024
10-Q
Quarterly Report
Apr 24, 2024
DEFA14A
DEFA14A
Apr 24, 2024
DEF 14A
DEF 14A
Apr 24, 2024
ARS
ARS
Mar 20, 2024
4
Insider Trading

Peers (Alternatives to Ovid therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
52.5B
6.8B
-18.41% 10.61%
-8.8
7.67
-64.45% -224.75%
28.2B
2.0B
9.73% -16.82%
-84.89
14.07
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.2B
2.5B
9.61% -12.35%
78.71
6.54
13.74% 186.89%
14.3B
3.8B
8.63% 2.12%
19.2
3.8
8.58% 129.81%
MID-CAP
5.1B
107.9M
-6.63% 69.33%
-9.37
48.09
54.84% -28.31%
4.6B
524.1M
-12.71% -56.08%
-11.07
8.82
394.93% 39.61%
3.6B
251.0M
-0.36% -15.32%
-12.24
14.45
73.58% -86.73%
3.2B
240.7M
1.47% -28.24%
-6.69
12.77
-1.03% -213.92%
2.5B
813.8M
-3.10% -36.23%
-1.5K
3.11
56.43% 98.83%
2.0B
996.6M
-10.70% 95.81%
-4.93
1.97
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.41% 18.74%
27.9
4.42
60.38% -34.49%
464.6M
881.7K
-5.58% 440.76%
-13.76
481.06
-77.61% 33.36%
206.5M
4.2M
-28.18% 49.63%
-1.65
49.65
-66.30% 48.24%
18.0M
2.1M
-6.22% 224.62%
-0.78
7.61
-13.45% 69.54%

Ovid therapeutics Inc News

Latest updates
MarketBeat21 Jun 202410:04 pm
Markets Insider18 Jun 202401:29 pm
InvestorPlace17 Jun 202404:39 pm

Ovid therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12022Q12021Q42021Q32021Q22021Q12020Q42020Q3
Revenue---109,05275,00066,00046,28011,1028,3275,5512,776---208,382,779107,648,4076,914,034
Operating Expenses-4.2%17,565,00018,330,14012,137,80414,246,98214,958,00012,219,19212,814,95814,304,28717,712,472-26,353,66511,681,73414,312,82631,825,46327,294,42923,317,696
  S&GA Expenses-6.8%7,168,0007,687,8986,805,2138,248,2168,344,0006,662,9857,631,7058,257,6179,880,203-8,264,0516,764,3416,629,15815,576,55410,410,6437,442,401
  R&D Expenses-2.3%10,397,00010,641,7425,332,5915,998,7666,615,0005,556,2075,183,2536,046,6707,832,269-18,089,6144,917,3937,683,66816,248,90916,883,78615,875,295
EBITDA Margin3.2%-169-174-161-245-59.79-35.69-1.60-0.81-0.540.740.600.811.12---
Income Taxes-------25,000--50,000--349,714-294,8291,473,084500,277--
Earnings Before Taxes23.7%-11,694,000-15,322,138-11,252,386-12,408,330-13,356,000-11,529,788-11,967,771-14,588,414-16,058,056--26,349,762-11,679,077-14,315,343176,507,584-22,029,501-16,424,789
EBT Margin3.2%-171-176-163-248-60.48-36.03-1.61-0.82-0.540.740.600.811.12---
Net Income23.7%-11,694,000-15,322,138-11,252,386-12,408,330-13,356,000-11,504,788-11,967,771-14,588,414-16,108,056--26,000,048-11,384,248-15,788,427176,007,307-22,029,501-16,424,789
Net Income Margin3.2%-171-176-163-248-60.45-36.05-1.60-0.81-0.550.740.590.801.10---
Free Cashflow-40.0%-16,719,000-11,945,092-10,056,245-11,712,971-12,126,000-9,295,671-12,694,973-14,328,508-20,132,354-12,160,462-12,160,462-10,894,066-19,405,376---
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-8.6%13214412513614315516517719119520721823776.0092.0045.0062.0081.0041.0055.0067.00
  Current Assets-15.0%93.0011092.0010212013114015617019020521623775.0090.0044.0061.0080.0039.0054.0063.00
    Cash Equivalents13.8%31.0027.0057.0072.0065.0047.0060.0075.0016919020221223372.0087.0041.0027.0042.0038.0047.0055.00
  Net PPE-10.8%1.001.001.001.001.001.001.001.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Liabilities-5.2%53.0056.0024.0026.0022.0023.0023.0025.0026.0015.0010.0011.0016.0032.0028.0015.0010.0011.0011.009.009.00
  Current Liabilities-22.4%9.0011.009.0010.007.007.00---15.0010.0011.0016.0022.0018.0015.0010.0011.0010.009.008.00
Shareholder's Equity-10.8%78.0088.0010111112113214215216518019720722144.0064.0030.0051.0070.0030.0045.0057.00
  Retained Earnings-4.2%-289-277-262-251-238-225-214-202-187-171-145-133-118-294-272-255-233-213-196-179-166
  Additional Paid-In Capital0.6%368366364362360358356354352351342341339338336286285283226225224
Shares Outstanding0.1%71.0071.0071.0071.0070.0070.0070.0070.0070.0070.0067.0067.00---------
Float----191---125---217---294---26.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-40.0%-16,700-11,931-10,051-11,705-12,112-9,175-12,676-13,288-20,086-11,998-10,872-19,416160,899-14,509-1,469-17,193-18,411-16,888-9,494-11,841-12,866
  Share Based Compensation10.0%1,9681,7891,6311,9481,9171,7301,7821,7201,3251,3151,1621,2571,3202,0512,6161,5551,3031,1271,1841,2521,643
Cashflow From Investing141.6%20,188-48,516-4,35920,06630,229-4,169-1,960-80,677-1,076-161-64.03-1,583-11.51-90.48-38.3030,9413,836-35,008-18.584,995-8.97
Cashflow From Financing-99.2%22830,03322421167.00-43.6082.0011033.00109549116130-23247,12016916.0055,88659.00-39130,986
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

OVID Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Total revenue$ 148$ 66
Operating expenses:  
Research and development10,3976,615
General and administrative7,1688,344
Total operating expenses17,56514,958
Loss from operations(17,417)(14,892)
Other income (expense), net5,7231,536
Loss before provision for income taxes(11,694)(13,356)
Provision for income taxes00
Net loss$ (11,694)$ (13,356)
Net loss per share, basic (in dollars per share)$ (0.17)$ (0.19)
Net loss per share, diluted (in dollars per share)$ (0.17)$ (0.19)
Weighted-average common shares outstanding, basic (in shares)70,716,92970,490,704
Weighted-average common shares outstanding, diluted (in shares)70,716,92970,490,704

OVID Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 30,772$ 27,042
Marketable securities59,48778,792
Prepaid expenses and other current assets2,9113,764
Total current assets93,170109,598
Long-term equity investments22,02217,626
Restricted cash1,9311,931
Right-of-use asset, net13,62813,894
Property and equipment, net686769
Other noncurrent assets174210
Total assets131,613144,027
Current liabilities:  
Accounts payable3,5963,703
Accrued expenses4,0396,525
Current portion, lease liability1,2681,246
Total current liabilities8,90311,474
Long-term liabilities:  
Lease liability14,43014,756
Royalty monetization liability30,00030,000
Total liabilities53,33356,230
Stockholders' equity:  
Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 1,250 shares issued and outstanding at March 31, 2024 and December 31, 202300
Common stock, $0.001 par value; 125,000,000 shares authorized; 70,783,961 and 70,691,992 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively7171
Additional paid-in-capital367,787365,591
Accumulated other comprehensive (loss) income(19)1
Accumulated deficit(289,560)(277,866)
Total stockholders' equity78,27987,797
Total liabilities and stockholders' equity$ 131,613$ 144,027
OVID
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, currently under preclinical stage, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV825, currently under preclinical stage, which has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, currently under preclinical stage, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
 CEO
 WEBSITEovidrx.com
 INDUSTRYBiotechnology
 EMPLOYEES40

Ovid therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Ovid therapeutics Inc? What does OVID stand for in stocks?

OVID is the stock ticker symbol of Ovid therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ovid therapeutics Inc (OVID)?

As of Fri Jun 21 2024, market cap of Ovid therapeutics Inc is 55.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OVID stock?

You can check OVID's fair value in chart for subscribers.

What is the fair value of OVID stock?

You can check OVID's fair value in chart for subscribers. The fair value of Ovid therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ovid therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OVID so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ovid therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether OVID is over valued or under valued. Whether Ovid therapeutics Inc is cheap or expensive depends on the assumptions which impact Ovid therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OVID.

What is Ovid therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 21 2024, OVID's PE ratio (Price to Earnings) is -1.09 and Price to Sales (PS) ratio is 186.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OVID PE ratio will change depending on the future growth rate expectations of investors.